SANTA CLARA, Calif., Aug. 9 /PRNewswire/ -- Applied Imaging Corp.
(Nasdaq: AICX) announced today that it had achieved a second straight quarter
with revenue growth of 38% over the same periods in 1999 and a reduced loss
for the second quarter and first half.
    The company's sales for the quarter and six months ending in June 2000
were at record levels of $4.3 million and $8.0 million, respectively. Sales
for both periods were 38% above the same periods of 1999.  In addition, the
operating loss for the quarter and six months narrowed to $0.5 million and
$1.8 million respectively, down from the prior year's $1.1 million and
$2.9 million. The loss per share was $0.04 in the quarter and $0.14 in the
first half, compared to the loss per share in the year earlier periods of
$0.09 and $0.25, respectively.
    "We are very pleased by the company's balanced performance in the second
quarter and first half," commented Jack Goldstein, PhD, Chairman and CEO.  "We
continue to see the favorable results of our strategy to focus on increased
sales of new products while leading consolidation within our core genetic
testing market.  New product sales totaled 17% of our instrument revenues
during the first half of the year.
    "Continued emphasis on expense management yielded an overall increase in
indirect expenses of less than 5% during the first half of the year, even as
we grew sales by almost 40%," added Goldstein.  "We further strengthened our
market position after the close of the second quarter with the
previously-announced acquisition of the US-based genetic imaging business  of
Perceptive Scientific Instruments, LLC.  The integration of this Texas-based
operation into our business is proceeding smoothly.
    "The second quarter also saw the issuance of a U.S. patent to the company
for a method of analyzing DNA from rare cells, such as cancer cells, that may
be present in extremely low numbers in tissues or blood.  Along with an
increasing number of scientific collaborations based around the company's
MDS(TM) system, we feel that we are extending our leadership in the
identification and genetic characterization of clinically-significant cancer
cells, as in the case of micrometastasis," Goldstein concluded.
    Applied Imaging Corp., based in Santa Clara, California, is the leading
supplier of automated imaging systems utilized in genetics and pathology
laboratories for the analysis of chromosomes in cancer and prenatal disorders.
The Company is expanding its efforts in scanning and imaging applications in
the cancer pathology field.  Applied Imaging has installed over 2000 systems
in 1000 laboratories in more than 35 countries.
    This press release contains forward looking statements as defined in the
Private Securities Litigation Reform Act of 1995, regarding, among other
matters, the Company's future financial performance as well as its research
and development and product development efforts.  Forward looking statements
address matters that are subject to a number of risks and uncertainties,
including the uncertainty of clinical studies and regulatory approvals.
Actual results could differ materially from those projected in the
forward-looking statement as a result of a number of factors including the
failure of the Company to successfully develop and commercialize its
micrometastasis or genetic instrument business, and other such factors as set
forth in the Company's form 10k for the year ended December 31, 1999 as filed
with the Securities and Exchange Commission.

    For additional information on Applied Imaging via fax, please dial
1-800-PRO-INFO, (732-544-2850 outside of the U.S.), code AICX.

Link to this page: